Neumega (Oprelvekin, Interleukin 11, IL-11)
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Von Willebrand Disease
Conditions
Von Willebrand Disease
Trial Timeline
Feb 1, 2008 → Jun 1, 2012
NCT ID
NCT00524225About Neumega (Oprelvekin, Interleukin 11, IL-11)
Neumega (Oprelvekin, Interleukin 11, IL-11) is a phase 2 stage product being developed by Pfizer for Von Willebrand Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00524225. Target conditions include Von Willebrand Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00524225 | Phase 2 | Terminated |
Competing Products
14 competing products in Von Willebrand Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate | Roche | Pre-clinical | 23 |
| Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents | Roche | Phase 3 | 77 |
| Oprelvekin, Interleukin 11, IL-11 | Pfizer | Phase 2 | 51 |
| recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11 | Pfizer | Phase 2 | 51 |
| efanesoctocog alfa (BIVV001) | Sanofi | Phase 1 | 32 |
| Biostate | CSL | Phase 3 | 76 |
| Voncento® | CSL | Pre-clinical | 22 |
| Blood coagulation Factor VIII and vWF, human | CSL | Approved | 84 |
| Biostate® + Biostate® | CSL | Phase 2/3 | 64 |
| VWF/FVIII products | CSL | Pre-clinical | 22 |
| Biostate | CSL | Phase 3 | 76 |
| Voncento | CSL | Approved | 84 |
| Alphanate SD/HT | Grifols | Approved | 82 |
| plasma-derived FVIII/VWF concentrate | Grifols | Approved | 82 |